

## THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following risks is quantified by the DCIS Recurrence Risk Score?
  - Risk of ipsilateral invasive breast cancer
  - Risk of DCIS local recurrence
  - Both a and b
- Which of the following patients meet the eligibility criteria for receiving IORT?
  - A patient with ER/PR-positive, HER2-negative, node-positive DCIS
  - A patient with ER/PR-positive, HER2-negative, node-negative IDC
  - Both a and b
- During IORT, approximately how far outside the tumor cavity does the radiation effect occur?
  - One centimeter
  - Two to 3 centimeters
  - Four to 5 centimeters
- The Alliance A11202 Phase III trial is evaluating the role of axillary lymph node dissection versus no axillary lymph node dissection after neoadjuvant chemotherapy for patients with sentinel lymph node-positive disease.
  - True
  - False
- Advantages of IORT as compared to whole-breast irradiation include \_\_\_\_\_.
  - Improved cosmetic outcomes
  - The fact that it is performed immediately after surgery (approximate 20-minute to 1-hour procedure time) rather than requiring multiple postoperative visits to the clinic
  - Both a and b
  - Neither a nor b
- The goal of the MINDACT trial, for which initial results were recently published, was to evaluate the benefit of genomic profiling with the \_\_\_\_\_ in addition to standard clinical-pathological criteria for identifying patients with early breast cancer and 0 to 3 positive lymph nodes who might safely forgo chemotherapy without compromising outcome.
  - PAM50 assay
  - 70-gene signature
  - 21-gene signature
- Which of the following outcomes has been observed since the publication of the 2014 SSO-ASTRO consensus guidelines endorsing “no ink on tumor”?
  - Fewer re-excisions after lumpectomy
  - Fewer mastectomies
  - Both a and b
- A study published by Bear and colleagues that randomly assigned patients with hormone receptor-positive, HER2-negative breast cancer and an intermediate 21-gene RS to neoadjuvant chemotherapy or neoadjuvant endocrine therapy demonstrated a higher pathologic complete response rate in favor of endocrine therapy.
  - True
  - False
- Which of the following categories reflects the mechanism of action of neratinib?
  - Antibody-drug conjugate
  - Anti-PD-1/PD-L1 antibody
  - Tyrosine kinase inhibitor
- A logistical challenge to using the 70-gene signature assay is that it continues to require only fresh frozen tissues.
  - True
  - False